Search This Blog

Wednesday, November 6, 2019

Aimmune Therapeutics EPS in-line

Aimmune Therapeutics (NASDAQ:AIMT): Q3 GAAP EPS of -$1.03 in-line.
Cash, equivalents and investments of $200.5M
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)